The structural logic of an antibody–drug conjugate explains why its immunological reach is broad. Each molecule combines a monoclonal antibody that recognises a tumour-associated antigen, a cleavable or non-cleavable linker and a cytotoxic payload, typically a tubulin-disrupting agent or a DNA-damaging topoisomerase I inhibitor. When the conjugate binds its target and is internalised, the payload is released inside the cancer cell. But the story does not end there. Many payloads, particularly those with membrane-permeable chemistry, diffuse out of the killed cell and kill neighbouring tumour cells regardless of antigen expression, a phenomenon known as bystander killing. That same permeability allows released drug to affect stromal and immune cells within the tumour, setting the stage for immune consequences that were largely unappreciated in the earliest clinical studies.

Central to the new paradigm is the concept of immunogenic cell death. Unlike silent apoptosis, immunogenic cell death releases damage-associated molecular patterns and tumour-associated antigens in a context that alerts the immune system. Preclinical work summarised in the review shows that maytansine-bearing conjugates induce hallmarks of immunogenic cell death selectively in antigen-positive cells, that brentuximab vedotin-driven microtubule disruption triggers endoplasmic reticulum stress leading to immunogenic cell death, and that trastuzumab deruxtecan activates the cGAS-STING pathway in gastric cancer models, upregulating HLA class I molecules and the chemokines CXCL9, CXCL10 and CXCL11. Datopotamab deruxtecan has likewise been shown to induce hallmarks of immunogenic cell death. The released antigens can then be taken up by dendritic cells, which mature and cross-present them to T cells, seeding a sustained adaptive antitumour response.

The antibody component contributes its own immunological layer. Fc-mediated functions such as antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis recruit natural killer cells and macrophages to destroy antibody-coated tumour cells. Tumour-associated macrophages can, in fact, contribute to antitumour activity through Fcγ receptor-mediated processing of antibody–drug conjugates, effectively acting as payload-delivery and antigen-release amplifiers. The choice of IgG subclass, glycosylation pattern and Fc engineering therefore has functional consequences: afucosylated antibodies augment CD16-mediated serial killing and interferon-γ secretion by natural killer cells, while Fc-silencing platforms can be used when effector engagement is undesirable. These design decisions determine whether a given conjugate behaves as a silent cytotoxic or as an active recruiter of innate immunity.

This biological foundation underpins the explosive clinical interest in combining antibody–drug conjugates with immune checkpoint inhibitors. The rationale is complementary: the conjugate converts an immunologically cold tumour into an inflamed one by releasing antigens and provoking dendritic cell activation, while checkpoint blockade removes the brakes on the T cells that are thereby primed. The most striking validation has come in urothelial cancer, where the combination of enfortumab vedotin with pembrolizumab produced practice-changing survival benefits in previously untreated metastatic disease, reshaping first-line standards of care. Perioperative studies of the same pairing have now reported positive results in bladder cancer, extending the strategy into earlier disease settings.

However, the review is careful to note that efficacy is not universal. In HER2-positive breast cancer, the phase 2 KATE2 trial of trastuzumab emtansine with atezolizumab did not meet its primary endpoint, and the phase 3 ASTEFANIA adjuvant trial of the same combination has not established the pairing in residual disease. By contrast, datopotamab deruxtecan plus durvalumab has shown encouraging activity in triple-negative breast cancer in the BEGONIA platform trial, including in first-line disease, and sacituzumab govitecan plus pembrolizumab outperformed chemotherapy plus pembrolizumab in PD-L1-positive metastatic triple-negative breast cancer in the randomised phase 3 ASCENT-04 study. Biomarker analyses from ASCENT-04 are now being used to understand which patients benefit, and the authors emphasise that biomarker-informed development will probably be required to avoid empiric, one-size-fits-all combination strategies.

Lung, gastric and other tumour types are also being tested. Trastuzumab deruxtecan has been combined with nivolumab and with pembrolizumab in phase 1b studies of HER2-expressing breast and urothelial cancers, and datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy has been evaluated in first-line non-small cell lung cancer in the TROPION-Lung02 trial. In gastric and gastroesophageal cancers, DESTINY-Gastric03 is exploring trastuzumab deruxtecan-based doublets and triplets including pembrolizumab. Disitamab vedotin plus toripalimab has produced positive phase 3 results in HER2-expressing urothelial cancer, and tisotumab vedotin combinations are under study in cervical cancer. The breadth of these programmes reflects a shared hypothesis: that payload-driven immune priming can convert checkpoint-refractory or checkpoint-naive tumours into responsive ones.

The next generation of conjugate design is shifting explicitly towards immune-oriented engineering. Bispecific constructs that bind two antigens, such as the EGFR–HER3 bispecific antibody–drug conjugate BL-B01D1 and izalontamab brengitecan, have shown clinical activity and, in some settings, phase 3 superiority over chemotherapy. Dual-targeting designs can also improve lysosomal trafficking and payload delivery, as demonstrated by conjugates targeting HER2 together with CD63. Immune-stimulating antibody conjugates represent another frontier: molecules such as BDC-1001, which couples a HER2-directed antibody to TLR7/8 agonists, and XMT-2056, a STING-agonist conjugate, are designed to deliver innate immune activation directly to the tumour. Probody technology, in which the antibody is masked until cleaved by tumour proteases, aims to widen the therapeutic window, and high-avidity, low-affinity antibody engineering can auto-tune delivery across heterogeneous antigen expression.

Targeting the tumour microenvironment itself is emerging as a complementary strategy. Conjugates directed at fibroblast activation protein can deplete cancer-associated fibroblasts that maintain an immunosuppressive stroma, while agents targeting B7-H3, B7-H4 and even PD-L1 itself repurpose immune checkpoint molecules as delivery portals, potentially killing checkpoint-ligand-expressing cells and simultaneously relieving immunosuppression. Novel payload classes are also in play, including splicing modulators with intrinsic immune-stimulatory properties and immunosuppressive payloads that could theoretically be used to dampen harmful inflammation. The review also highlights TCR-mimic antibody–drug conjugates capable of targeting intracellular oncoproteins such as WT1 and MART-1 through peptide–MHC complexes, dramatically expanding the pool of druggable targets beyond surface antigens.

Safety considerations temper the enthusiasm. The same immune mechanisms that enhance efficacy can contribute to toxicity, and the interstitial pneumonitis associated with trastuzumab deruxtecan has been linked in preclinical work to perivascular niche–resident alveolar macrophages, suggesting an immune-mediated component. Fcγ receptor-dependent internalisation of conjugate aggregates can drive off-target cytotoxicity, and immune complex clearance mechanisms help explain some adverse events. A companion review in the same journal addresses the clinical toxicity of antibody–drug conjugates and their combinations with checkpoint inhibitors. The overall message from the Milan-based and Chapel Hill-based team is that antibody–drug conjugates should no longer be viewed merely as targeted cytotoxics but as modulators of tumour–immune interactions, a repositioning that will shape monotherapy use, combination regimens and drug design for years to come.

Subject of Research: Immunological mechanisms of action of antibody–drug conjugates and their combination with immune checkpoint inhibitors in cancer therapy

Article Title: Exploring the immunological effects of antibody–drug conjugates

Article References: Zagami, P., Trapani, D., Marra, A., Carey, L. A., & Curigliano, G. (2026). Exploring the immunological effects of antibody–drug conjugates. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01209-z

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01209-z

Keywords: antibody–drug conjugates, immunogenic cell death, immune checkpoint inhibitors, tumour microenvironment, dendritic cells, antibody-dependent cellular cytotoxicity, trastuzumab deruxtecan, enfortumab vedotin, bispecific antibodies, cGAS-STING pathway, breast cancer, urothelial cancer

The drug in question is sacituzumab govitecan, an engineered molecule that fuses two very different components into a single therapeutic agent. One end is an antibody that recognizes TROP-2, a cell-surface protein found at high levels on many epithelial cancers, including the majority of triple-negative breast tumors. The other end is SN-38, the active metabolite of the widely used chemotherapy drug irinotecan, which poisons dividing cells by blocking the topoisomerase I enzyme and triggering lethal DNA damage. A cleavable chemical linker holds the two together, designed to remain stable in the bloodstream and then release its toxic payload once the antibody docks onto a tumor cell and the complex is internalized. The result is a delivery system that concentrates a potent cell-killing drug where it is needed most, while sparing healthy tissue more effectively than conventional chemotherapy ever could.

Sacituzumab govitecan earned regulatory approval on the strength of randomized clinical trials, but trial populations are notoriously selective. Patients enrolled in pivotal studies tend to be younger, fitter, and free of the organ dysfunction and competing illnesses that characterize many people treated in everyday clinics. The question of whether the drug performs as well in the messy reality of routine oncology care is therefore far from academic. That is precisely the question addressed by a team of researchers led by Marcin Kubeczko of the Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice, Poland, and Mirosława Püsküllüoğlu of the institute’s Krakow branch, in a secondary analysis of the CEBCC-102 real-world cohort published in BMC Cancer.

The study pooled data from cancer centers across Poland, the Czech Republic, and Slovakia, creating one of the larger real-world datasets on this drug in the region. The researchers restricted their analysis to patients who received sacituzumab govitecan as third-line or later systemic therapy for metastatic disease—a group so heavily pretreated that many had exhausted nearly every standard option. To qualify, patients needed either at least three prior chemotherapy lines for metastatic disease, or prior chemotherapy given before surgery with the intent to cure followed by at least two further chemotherapy lines after relapse. In total, 107 patients met these criteria. Sixty-seven of them had received exactly three prior chemotherapy lines, while forty had endured four or more, a testament to both the tenacity of the disease and the determination of the clinicians treating it.

The headline numbers tell a story of modest but genuine activity. After a median follow-up of 19.6 months, estimated using the reverse Kaplan–Meier method, patients treated with sacituzumab govitecan lived a median of 4.1 months before their disease progressed, with 37.3 percent remaining progression-free at six months. Median overall survival reached 10.6 months, and 42.7 percent of patients were still alive one year after starting treatment. For a population in which many would previously have had a life expectancy measured in a handful of months, these figures represent a real extension of time, even if they fall short of the dramatic gains seen in earlier treatment settings or in trial populations selected for better baseline health.

Perhaps the most intriguing finding concerns the number of prior treatments. The researchers compared patients who had received three prior chemotherapy lines with those who had received four or more, expecting to see a clear gradient of worsening outcomes with increasing pretreatment. Instead, they found essentially no difference: progression-free survival was 4.1 months in the three-line group versus 3.7 months in the more heavily treated group, and overall survival was 10.5 versus 11.7 months, with neither comparison approaching statistical significance. On its face, this might suggest that the drug works equally well no matter how much treatment a patient has already received—an idea with profound implications for how late in the disease course the drug might be deployed.

The authors themselves, however, urge caution against that interpretation, and their reasoning reveals the subtle statistical traps inherent in real-world evidence. Patients who survive long enough to receive a fourth, fifth, or sixth line of chemotherapy are, by definition, a selected group: they tend to have slower-growing tumors, better performance status, and fewer comorbidities than patients who deteriorate rapidly after their third line. This survivorship bias means the heavily pretreated subgroup starts with an advantage that can mask the true cost of additional prior therapy. Selection bias compounds the problem, because clinicians choose whom to treat with the drug, and those choices are informed by factors that never appear fully in any dataset. The absence of a survival difference across pretreatment groups, the researchers conclude, should not be read as proof of equivalent efficacy regardless of prior exposure.

On the safety front, the study delivered reassuring news. Sacituzumab govitecan was generally well tolerated across the cohort, with no unexpected toxicities emerging and, critically, no grade 5 adverse events—meaning no treatment-related deaths were recorded. This matters because the drug’s known side-effect profile, which includes neutropenia and diarrhea, can be harder to manage in patients whose bone marrow and digestive systems have already been stressed by years of chemotherapy. The fact that a real-world population, typically frailer than trial participants, tolerated the drug without surprises strengthens confidence that the safety data from registration trials translate faithfully to ordinary clinical practice.

The broader significance of the study lies in its geography and its method. Central and Eastern European countries are often underrepresented in global oncology trials, and real-world evidence from the region has been sparse. By assembling a multicenter cohort spanning three countries and dozens of institutions, the CEBCC-102 collaboration has produced data that reflect the actual conditions under which most of the world’s cancer patients are treated: variable resources, diverse patient populations, and treatment decisions made without protocol-mandated eligibility criteria. Such studies cannot replace randomized trials, but they serve as an essential reality check, revealing whether the promise of clinical research survives contact with clinical routine.

For patients with metastatic triple-negative breast cancer and the oncologists who treat them, the practical message is one of cautious optimism. Sacituzumab govitecan retains meaningful activity even after multiple lines of chemotherapy, and it can be given safely to clinically fit patients late in their treatment journey. The drug is not a cure, and the survival gains, while real, remain measured in months. But in a disease where every additional option has historically come at the cost of mounting toxicity and diminishing benefit, a targeted agent that extends life while sparing patients the worst ravages of conventional chemotherapy represents genuine progress—and a template for how antibody-drug conjugates may continue to reshape the treatment of hard-to-target cancers.

Subject of Research: Real-world effectiveness of sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer

Article Title: Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort

Article References: Marcin, K., Aleksandra, K., Polakiewicz-Gilowska, A., Małgorzata, P., Justyna, Ż., Miloš, H., Renata, S., Hana, Š., Miroslava, M., Agnieszka, M., Karolina, W.-S., Maja, L.-H., Anika, P., Daniel, K., Jan, Š., Iveta, K., Iwona, D., Magdalena, S.-R., Tomasz, C., … Mirosława, P. (2026). Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17103-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17103-x

Keywords: sacituzumab govitecan, triple-negative breast cancer, antibody-drug conjugate, metastatic breast cancer, real-world evidence, TROP-2, progression-free survival, overall survival, late-line therapy, Central Europe, oncology, chemotherapy

The starting point for this transformation is a sober clinical reality. Although most patients with marginal zone lymphoma experience favorable outcomes, approximately twenty percent relapse or progress early, within twenty-four months of initial treatment. That minority represents the central unsolved problem in the field. For these patients, the disease often reveals a more aggressive biology than its indolent label suggests, and the therapeutic options available after frontline therapy have historically been limited. It is precisely this population that the new generation of targeted and immune-based therapies aims to serve, and the review places their needs at the center of its analysis.

What has made precision medicine possible in this disease is the accumulation of detailed molecular profiling. The authors describe recurrent alterations in three major signaling axes: the B-cell receptor pathway, the NF-κB pathway, and NOTCH signaling. These are not random findings. Chronic antigen drive through the B-cell receptor, constitutive activation of NF-κB-dependent survival programs, and dysregulated NOTCH signaling together form the wiring diagram of the malignant marginal zone B cell. Layered on top of these are epigenetic changes that alter gene expression without changing the underlying DNA sequence, as well as abnormalities in the immune microenvironment that surrounds and supports the tumor. Each of these layers offers a potential point of therapeutic intervention, and each has spawned a corresponding class of drugs now in clinical evaluation.

Among the targeted agents, the strongest clinical evidence belongs to Bruton tyrosine kinase inhibitors, known as BTK inhibitors. BTK is a signaling molecule essential to B-cell receptor function, and blocking it effectively starves the malignant cell of one of its principal survival signals. In relapsed or refractory marginal zone lymphoma, these agents have produced durable responses and have become a cornerstone of second-line and later therapy. The review emphasizes, however, that their use is not without complications. First-generation BTK inhibitors carry risks of atrial arrhythmias, bleeding, and hypertension, and resistance can emerge through mutations in BTK itself or in downstream signaling components. Newer, more selective inhibitors aim to retain efficacy while narrowing the toxicity profile, and the choice of agent increasingly depends on patient comorbidities and treatment goals.

Beyond BTK inhibition, the review surveys two additional classes of small-molecule targeted therapy. BCL-2 inhibitors exploit a different vulnerability: the overexpression of an anti-apoptotic protein that allows lymphoma cells to evade programmed cell death. By releasing the mitochondrial brake on apoptosis, these agents can trigger tumor cell death directly, and they have been evaluated across B-cell malignancies with growing interest in marginal zone lymphoma. PI3K inhibitors, meanwhile, target a lipid kinase downstream of the B-cell receptor that promotes cell survival, proliferation, and trafficking. Their clinical history in indolent lymphomas has been complicated by immune-mediated toxicities, including colitis and pneumonitis, which has prompted closer regulatory scrutiny and a more careful approach to patient selection. The review stresses that efficacy must always be weighed against these safety considerations, particularly in an indolent disease where patients may live with treatment consequences for decades.

Monoclonal antibodies remain a foundational element of the therapeutic arsenal, and the review highlights how this class continues to evolve. Antibodies directed against CD20 have long formed the backbone of frontline treatment, and novel antibodies with enhanced immune-recruiting properties are extending this approach. Antibody-drug conjugates represent a further refinement, coupling the targeting specificity of an antibody to a potent cytotoxic payload that is released only after the drug reaches the tumor cell. This design concentrates chemotherapy’s killing power where it is needed while limiting collateral damage to healthy tissue. The result is a class of agents that blurs the traditional line between targeted therapy and cytotoxic treatment, offering a middle path with distinct pharmacological logic.

Perhaps the most striking advances described in the review lie in the realm of immune-based therapeutics. Bispecific antibodies are engineered molecules capable of binding two targets simultaneously: one arm attaches to a marker on the malignant B cell, while the other engages CD3 on T cells, physically bridging the two and forcing the immune system to attack the tumor. These off-the-shelf agents have demonstrated impressive activity in other indolent lymphomas and are being evaluated in marginal zone lymphoma across treatment settings. Chimeric antigen receptor T-cell therapy, or CAR-T, takes a different route to the same goal. A patient’s own T cells are harvested, genetically engineered to recognize a B-cell antigen such as CD19, expanded in the laboratory, and reinfused. The engineered cells then hunt down and destroy lymphoma cells throughout the body. For patients whose disease has failed multiple prior lines of therapy, these cellular and bispecific approaches have opened doors that simply did not exist a decade ago.

The review is careful to frame these advances within their limitations. Clinical evidence for several of the newer modalities in marginal zone lymphoma specifically remains less mature than in other B-cell malignancies, and the heterogeneity of the disease itself complicates interpretation. Marginal zone lymphoma encompasses distinct subtypes arising in different anatomical sites, from the stomach to the spleen to the lymph nodes, each with its own biology and treatment considerations. Extrapolating results from one subtype or from related lymphomas carries genuine uncertainty. The authors also emphasize the importance of biomarkers: molecular alterations identified at diagnosis or relapse may eventually guide which patients benefit from which agents, but validated predictive markers remain an aspiration rather than a routine clinical reality for many of these drugs.

Questions of treatment sequencing loom large over the entire field. With BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, antibody-based approaches, bispecifics, and CAR-T all now available or in development, clinicians face an increasingly complex decision tree. Should a novel targeted agent be deployed at first relapse, or should conventional therapy be exhausted first? Can immune-based approaches such as bispecific antibodies or CAR-T be moved earlier in the disease course, where patients may be fitter and more likely to tolerate them? How should resistance to one class of agent influence the choice of the next? The review addresses these questions directly, arguing that rational sequencing, informed by molecular profiling and by the toxicity profiles of successive therapies, will be essential to maximizing the benefit each approach can deliver over a patient’s lifetime.

What emerges from this comprehensive synthesis is a portrait of a disease in transition. Marginal zone lymphoma, once treated with a relatively blunt toolkit, is becoming a testing ground for the full breadth of modern cancer therapeutics, from kinase inhibitors that rewire intracellular signaling to engineered immune cells that patrol the body seeking malignant targets. The molecular alterations that drive the disease, in B-cell receptor, NF-κB, and NOTCH pathways, in the epigenome, and in the tumor microenvironment, are no longer merely descriptive findings; they are the blueprint for drug development. For the majority of patients who do well with current therapy, these advances promise more tailored and less toxic options when treatment is needed. For the twenty percent who relapse early, they represent something more consequential: a genuine expansion of hope, grounded in a deeper understanding of what keeps their cancer alive and how to take it apart.

Subject of Research: Targeted and immunotherapeutic strategies for marginal zone lymphoma

Article Title: Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma

Article References: Wang, X., Xiong, Q., Zhou, Y., Yu, M., & Li, F. (2026). Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-026-07288-3

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07288-3

Keywords: marginal zone lymphoma, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, bispecific antibodies, CAR-T therapy, immunotherapy, targeted therapy, NF-κB signaling, NOTCH signaling, B-cell lymphoma, antibody-drug conjugates

The volume’s review article turns its attention to one of the most closely watched corners of modern oncology: antibody-drug conjugates, or ADCs, in colorectal cancer. These engineered molecules combine an antibody that homes in on tumor cells with a potent cytotoxic payload, aiming to concentrate chemotherapy-like killing power on malignant tissue while sparing healthy cells. The authors chart the rapidly evolving clinical landscape of ADCs in colorectal carcinoma, highlighting the recent approval of trastuzumab deruxtecan, known as T-DXd, for HER2-positive disease as a milestone entry into this treatment arena. By dissecting clinical performance, molecular design considerations and future directions, the review positions ADCs as a promising targeted option for colorectal cancer patients whose clinical needs remain unmet by existing therapies.

Structural biology and fragment-based drug design feature prominently among the original research contributions. In one study, researchers used an X-ray fragment screening approach to identify a series of allosteric inhibitors that selectively target adenosine monophosphate deaminase 2, or AMPD2, over other AMPD isozymes. Traditional inhibitors that bind the enzyme’s active site have struggled with poor selectivity, but by iteratively merging and optimizing fragments, the team developed potent compounds that bind a previously uncharacterized allosteric site. The resulting molecules, designated 10g and 10h, offer valuable chemical tools for probing AMPD2’s roles in nucleotide metabolism, energy homeostasis and immune oncology, an area of growing interest as metabolism becomes a central theme in cancer immunology.

Biosensor technology also received a significant upgrade in the volume. A second structural study demonstrated that grating-coupled interferometry, or GCI, provides a powerful platform for characterizing interactions between G protein-coupled receptors and their ligands. Using the adenosine A2A receptor as a model system, the researchers showed that GCI delivers high-quality kinetic data comparable to the established Biacore technology while enabling rapid affinity and thermodynamic profiling from single-concentration injections. The team validated the approach through kinetic fragment screening of a 704-member library, identifying specific binders that were confirmed by nano differential scanning fluorimetry. The work establishes GCI as an information-rich tool for early-stage GPCR drug discovery, a field that accounts for a large share of current pharmaceutical targets.

Perhaps the most striking example of AI’s expanding role comes from a multi-omics study of Mycobacterium avium infection, an insidious pathogen notorious for its persistence in patients with compromised lungs. By integrating single-cell RNA sequencing with machine learning, the researchers mapped the immune landscape of MAV infection and uncovered a monocyte-driven MIF-APP signaling axis that recruits macrophages and locks them into a hyper-inflammatory state. This mechanism helps explain a long-standing paradox: patients mount vigorous inflammation yet fail to clear the pathogen. The computational analysis also yielded a five-gene diagnostic signature with an area under the curve exceeding 0.88, a level of accuracy that could translate into clinically useful tests. In parallel, the team identified Wogonin, a natural product-derived compound, as a potential host-directed therapeutic that targets STAT3 and TNF to break the immune impasse, shifting the treatment strategy from attacking the bacterium directly to reprogramming the host response.

Data mining of previously deposited screening data proved equally productive in the antiviral arena. Applying a computational prioritization strategy to a legacy screen of nearly 300,000 small molecules, researchers identified three distinct chemical scaffolds that inhibit Lassa virus cell entry with potencies as low as 10 nanomolar and strong selectivity over related viruses. Mechanistic work indicated that these compounds act at the membrane fusion stage by targeting pH-sensitive regions of the viral glycoprotein, the molecular machinery the virus uses to slip into cells after being engulfed. The study highlights how combined computational and experimental approaches can extract new value from old data, a strategy that is increasingly attractive as screening datasets accumulate faster than they can be fully analyzed.

Deep learning also made its mark in vaccine development. Researchers unveiled CellVision, a deep learning-based image analysis platform that fully automates viral plaque counting in high-throughput immuno-plaque assays. The system accurately segments fused plaques and distinguishes them from other objects without any manual image review, a task that has traditionally consumed enormous amounts of technician time and introduced inter-operator variability. Integrated into Merck & Co., Inc.’s µPlaque assay to support an investigational dengue vaccine, CellVision outperformed a commercial alternative and sets a new benchmark for AI-powered analysis in antiviral vaccine discovery, where assay throughput and reproducibility directly influence how quickly candidates can advance.

Cancer drug screening gained precision from a tumor-versus-normal comparison strategy aimed at nasopharyngeal carcinoma, an epithelial cancer strongly associated with Epstein-Barr virus. Using high-throughput drug screening against paired EBV-positive and EBV-negative NPC cell lines alongside normal epithelial controls, researchers identified the AKT inhibitor capivasertib as a highly selective anti-NPC agent that spares healthy cells. The compound synergized with platinum-based chemotherapy, enhanced radiosensitivity, and significantly prolonged survival when combined with cisplatin in xenograft models. The results provide a strong rationale for clinical evaluation of capivasertib in advanced nasopharyngeal carcinoma, where treatment options have remained limited.

Even the statistics of drug screening came under scrutiny. A comparative analysis of statistical tests for count data, such as the numbers of cells in different states, found that simple t tests perform as well as or better than specialized count-based methods at maintaining false-positive rates, with no disadvantage in detecting real differences. The findings reassure researchers that converting count data to percentages and analyzing them with t tests is a valid and effective approach under typical wet-lab conditions, a practical conclusion that could simplify analysis pipelines in countless laboratories.

Rounding out the volume, a short communication described a high-throughput time-resolved fluorescence resonance energy transfer, or TR-FRET, assay developed to interrogate the interaction between the immune checkpoint LILRB4, also known as ILT3, and its ligand SCG2. This pathway drives myeloid-mediated immunosuppression in the tumor microenvironment, a major obstacle to effective cancer immunotherapy. Pilot screening identified two compounds, BMS-813160 and PSB-603, that dose-dependently inhibit the interaction with micromolar potency, providing the first small-molecule modulators of the LILRB4-SCG2 axis. Alongside a new homogeneous OMEGA assay for detecting extracellular AGR2, a protein linked to tumor progression, across diverse biological fluids with a dynamic range from 0.02 to 300 nanograms per milliliter, these contributions underscore the volume’s central message: from fragment merging and biosensors to machine learning diagnostics and automated image analysis, the drug discovery toolkit is becoming faster, smarter and more data-driven at every step.

Subject of Research: AI-driven analytics and data-mining strategies for drug discovery

Article Title: AI-driven analytics and data-mining strategies for drug discovery

Article References: AI-driven analytics and data-mining strategies for drug discovery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, drug discovery, SLAS Discovery, machine learning, antibody-drug conjugates, colorectal cancer, Mycobacterium avium, Lassa virus, deep learning, high-throughput screening, nasopharyngeal carcinoma, immune checkpoint

The structural logic of MUC1 explains both its normal function and its malignant potential. The MUC1 gene, located on chromosome 1q21-24, encodes a single polypeptide of 120 to 225 kilodaltons that balloons to 250 to 500 kilodalts after glycosylation. Its extracellular region contains between 20 and more than 100 tandem repeats of a 20-amino-acid sequence, each repeat carrying five O-glycosylation sites, producing a glycocalyx that extends hundreds of nanometers beyond the cell surface. Critically, the protein undergoes autoproteolysis within its SEA domain, cleaving at a GSVVV motif into two subunits that remain associated as a non-covalent heterodimer: MUC1-N, the sheddable, sugar-laden protective arm, and MUC1-C, a compact transmembrane unit with a 58-amino-acid extracellular domain, a 28-amino-acid membrane anchor, and a 72-amino-acid cytoplasmic tail that functions as the molecule’s oncogenic brain. In normal epithelia, the complex sits strictly at the apical membrane; in tumors, it spreads across the entire cell surface and into the cytoplasm, its O-glycans truncated into tumor-associated forms such as Tn, sTn, TF, and sTF.

MUC1-C is where the real molecular action happens. Its extracellular domain carries an NLT motif whose N-glycans recruit galectin-3, which in turn bridges MUC1-C to EGFR and other receptor tyrosine kinases at the membrane. Its cytoplasmic tail bristles with 12 documented and putative phosphorylation sites that serve as substrates for EGFR, Src-family kinases, ABL, GSK3β, and ZAP70, creating docking platforms for effectors such as PI3K, SRC, and GRB2. A CQC motif near the membrane, activated by reactive oxygen species, drives MUC1-C oligomerization and directs the protein to the nucleus via importin-β and to mitochondria via HSP70/90 chaperones, where it blocks the intrinsic apoptotic pathway. In the nucleus, MUC1-C binds β-catenin and TCF4 to occupy the CCND1 promoter, recruits p300 to acetylate histone H3K27, and interacts directly with p53, IKKα, IKKβ, and RelA, placing it at the command posts of the Wnt, p53, and NF-κB pathways simultaneously.

Two auto-inductive feedback loops give this signaling web its self-sustaining, pathological persistence. MUC1-C binds JAK1 and STAT3 directly, promoting STAT3 phosphorylation; activated STAT3 then binds the MUC1 promoter, cranking out more MUC1-C in a loop that is transient during normal inflammatory responses but constitutively locked on in carcinomas. A parallel loop operates with NF-κB, which MUC1-C activates both by stimulating the IKK complex and by physically blocking NF-κB’s inhibitor IκBα. Beyond these canonical circuits, the review highlights MUC1-C’s emerging role as an epigenetic master regulator: the protein induces the Yamanaka pluripotency factors OCT4, SOX2, KLF4, and MYC, binds the Polycomb marks H2A K119 ubiquitylation and H3K27 methylation, and reshapes chromatin accessibility at JUN/AP-1-regulated enhancers, thereby enforcing the lineage plasticity and stem-like state that make cancer cells so hard to eradicate.

The downstream consequences for anti-tumor immunity are stark. MUC1-C’s cytoplasmic tail sustains a JAK1-STAT1-IRF1 transcriptional axis that upregulates IDO1 and COX2/PTGES, depleting tryptophan, accumulating kynurenine, and generating prostaglandin E2, together halting CD8-positive T-cell cycling and pushing regulatory T-cell differentiation. MUC1-C also delivers mutant p53 and β-catenin to the CTGF promoter, unleashing connective tissue growth factor that recruits cancer-associated fibroblasts and deposits a physical collagen barrier. Analyses of TCGA, METABRIC, and single-cell datasets consistently show that MUC1-high tumors are depleted of cytotoxic T cells, Th1 helpers, B cells, and M1 macrophages while enriched in Tregs, myeloid-derived suppressor cells, and M2-polarized tumor-associated macrophages. Even at the glycan level, sTn-decorated MUC1 engages Siglec-9 on myeloid cells to trigger a calcium-MEK-ERK program that completes macrophage polarization and renders tumors refractory to PD-1 blockade, effectively converting an immunological hotbed into what the authors describe as an ice cave.

Disease-specific evidence reinforces the breadth of this mechanism. In breast cancer, high MUC1 mRNA predicts reduced overall, disease-free, and recurrence-free survival; MUC1-C interacts with estrogen receptor alpha to drive tamoxifen resistance, forms a self-sustaining loop with TWIST1 that underlies paclitaxel resistance, and cooperates with STAT1 in roughly 15 percent of primary breast tumors, a co-expression pattern linked to poor outcomes. In non-small cell lung cancer, MUC1-C drives acquired resistance to osimertinib by sustaining ERK and AKT signaling through EGFR/MET heterodimerization, occupies the CD274 promoter to induce PD-L1, and represses immune genes such as TLR9 and IFN-γ through ZEB1. In pancreatic ductal adenocarcinoma, where MUC1 is overexpressed in more than 60 percent of cases, the protein stabilizes HIF-1α, accelerates glycolysis and pyrimidine biosynthesis, and accumulates endogenous dCTP that directly antagonizes gemcitabine, while also suppressing BRCA1 and blunting radiosensitivity.

The oncogenic reach extends into blood cancers and chronic inflammatory disease. MUC1 is overexpressed specifically in acute myeloid leukemia stem cells, where it stabilizes both wild-type and mutant FLT3 receptors and activates the AKT/ERK/STAT5 axis; the peptide inhibitor GO-203 selectively eliminates these stem cells while sparing normal hematopoiesis. In chronic myeloid leukemia, MUC1 physically stabilizes the Bcr-Abl fusion protein and maintains imatinib resistance, while in multiple myeloma, aberrantly glycosylated MUC1 appears on 73 percent of malignant plasma cells and drives the WNT/β-catenin-TCF4-MYC survival program alongside redox balance maintained with TIGAR. Outside oncology, loss of MUC1 in chronic obstructive pulmonary disease correlates with steroid resistance, aberrant MUC1 glycosylation in ulcerative colitis promotes colitis-associated colorectal cancer, and frameshift mutations in the VNTR region cause autosomal dominant tubulointerstitial kidney disease through endoplasmic reticulum stress.

Therapeutically, the field has learned hard lessons but is now fielding a far more sophisticated arsenal. Only two MUC1-targeted drugs have reached phase III trials, the liposomal peptide vaccine Tecemotide and the poxviral vector TG4010, and both failed to improve survival, a result attributed in part to MUC1’s poor intrinsic immunogenicity and the redundancy of the pathways it controls. The current generation of approaches is more precise: monoclonal antibodies such as DMB5F3 against the SEA domain and GGSK-1/30, whose zirconium-89-labeled form achieved over 50 percent injected dose per gram tumor uptake with 96.5 percent diagnostic specificity in PET imaging; antibody-drug conjugates including 3D1-MMAE, which eradicated MUC1-positive lung and breast tumors in transgenic mice without toxicity; CAR-T cells engineered against the tumor-specific Tn-glycoform of MUC1, which spare normal epithelium; armored allogeneic CAR constructs with PD1 and TGFBR2 knockout and IL-12 insertion; oncolytic adenoviruses encoding MUC1-CD3 bispecific T-cell engagers; and RNA interference delivered by MUC1-aptamer-tethered nanoparticles.

The review’s authors are candid about the remaining obstacles. Because MUC1-C sits at the hub of so many compensatory networks, single-agent inhibition invites bypass signaling through AXL, MET, or downstream PI3K and MEK pathways, and chronic blockade can push cells toward stem-like or neuroendocrine phenotypes through epigenetic remodeling. The most promising path, they argue, is rational combination and sequencing: pairing MUC1-C inhibitors with PI3K/AKT/mTOR blockade, PD-1 antibodies, or epigenetic drugs such as decitabine, or using MUC1-C inhibition as a priming step to reverse epithelial-mesenchymal transition before conventional chemotherapy or checkpoint inhibitors. Preclinical combination studies already show dramatic gains, with a MUC1-MBP vaccine plus anti-PD-1 raising tumor clearance in mice from 20 to 80 percent. With nanodelivery systems, cell-carrier platforms, and MUC1-triggered smart materials now entering the design space, the molecule once dismissed after two failed phase III trials is being repositioned as what may become one of oncology’s most consequential pan-cancer targets, provided that mechanistic depth and rigorous clinical validation keep pace with the enthusiasm.

Subject of Research: The role of the MUC1 mucin, particularly its MUC1-C subunit, in oncogenic signaling, immune evasion, and targeted cancer therapy development

Article Title: MUC1 in cancer

Article References: Qian, K., Zhang, Y., Zhou, Q., Zhou, J., Wu, X., Zhu, J., Pan, Y., Wu, Z., Li, S., Lin, Y., Lyu, F., Chen, S., & Sun, H. (2026). MUC1 in cancer. Holistic Integrative Oncology, 5(1), Article 32. https://doi.org/10.1007/s44178-026-00257-w

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00257-w

Keywords: MUC1, MUC1-C, cancer biology, oncogenic signaling, immune evasion, immunotherapy, CAR-T cells, antibody-drug conjugates, cancer vaccines, drug resistance, epigenetic reprogramming, tumor microenvironment

The trial’s origins lie in a deliberate, consensus-driven prioritisation exercise. At the second Paediatric Strategy Forum of ACCELERATE, an international multi-stakeholder organisation that brings together clinicians, regulators, industry, patients and families, experts concluded in November 2017 that no single country could mount meaningful trials in this rare disease setting alone. They agreed that an international approach was critical, and that robust prioritisation of novel targeted agents was essential so that only those showing maximum potential would advance into clinical investigation. That conclusion has now crystallised into a fully designed protocol, published in BMC Cancer, with trial registration on ClinicalTrials.gov under identifier NCT05991388 since July 2023.

Glo-BNHL is structured as a platform trial, a design philosophy borrowed from other areas of medicine where speed and flexibility matter most. Rather than testing one drug against another in a fixed comparison, a platform trial provides a permanent clinical infrastructure into which multiple treatment arms can be slotted. In this case, the ACCELERATE Forum identified three classes of agents for immediate prioritisation: bispecific antibodies, antibody-drug conjugates combined with standard chemotherapy, and chimeric antigen receptor T-cells, better known as CAR T-cells. Each class represents a distinct strategy for attacking malignant B-cells, and promising agents from each will be evaluated in parallel treatment arms running concurrently within the same study.

The technical sophistication of the trial lies in its adaptive Bayesian statistical design. Bayesian methods allow researchers to update the probability that a treatment is working as data accumulate, rather than waiting until a pre-fixed sample size has been exhausted. This is crucial in a rare paediatric cancer, where the number of eligible patients at any given time is small and every participant counts. The design facilitates efficient GO or NO-GO decisions even with small numbers of participants registered into each arm. Each treatment arm begins with an initial stage evaluating efficacy, and if the signals are promising, an expansion stage can follow to provide confirmatory analysis. Equally important, if the scientific landscape shifts and prioritisation of drug classes changes, the adaptive architecture allows treatment arms to be added or removed to reflect the new evidence, keeping the platform current without the delay of launching an entirely new trial.

The first two agents to enter the platform illustrate the diversity of the approaches being tested. Treatment Arm I will evaluate odronextamab, a bispecific antibody supplied by Regeneron, which is also providing funding to support a fit-for-filing trial for that arm. Bispecific antibodies are engineered proteins capable of binding two targets at once, in this case simultaneously tethering a malignant B-cell to a cytotoxic T-cell so the immune cell can destroy the cancer. The primary outcome for this arm is the occurrence of an objective response after 12 weeks of treatment. Treatment Arm II will evaluate loncastuximab tesirine, an antibody-drug conjugate supplied by ADC Therapeutics, combined with a modified R-ICE chemotherapy regimen. Antibody-drug conjugates work as targeted delivery vehicles, using an antibody to ferry a potent cytotoxic payload directly to CD19-expressing tumour cells while limiting collateral damage to healthy tissue. For this arm, the primary outcome is the occurrence of a complete response within a maximum of three treatment cycles.

The third prioritised class, CAR T-cells, involves a fundamentally different therapeutic logic. Instead of administering a drug, clinicians collect a patient’s own T lymphocytes, engineer them in the laboratory to express a chimeric antigen receptor that recognises a marker on the surface of malignant B-cells, expand the modified cells, and infuse them back into the patient. The trial’s primary outcome for this arm is the occurrence of an objective response following CAR T-cell infusion. Because these living drugs can trigger distinctive immune-mediated toxicities, the protocol pays close attention to adverse events of special interest, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, both of which are graded according to standards established by the American Society for Transplantation and Cellular Therapy.

Eligibility for the trial is carefully defined to capture the right patient population at the right moment. Participants must be 25 years old or younger, with histologically proven mature B-cell non-Hodgkin lymphoma at initial diagnosis and radiologically or histologically proven disease at first or subsequent relapse, or refractory disease that failed to respond to frontline therapy. Patients must have a Karnofsky or Lansky performance status of at least 50, a measure of functional wellbeing that ensures participants are well enough to tolerate investigational treatment. Written informed consent is required from participants or, for children, from parents or legal guardians, and the protocol received initial ethical approval in the United Kingdom from the London City and East Research Ethics Committee in October 2023.

The scale of international coordination behind Glo-BNHL is itself a technical achievement. The trial is led from the United Kingdom, anchored at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, with national coordinating centres in Australasia, Europe and North America. Collaborating organisations include the European Inter-Group for Childhood Non-Hodgkin Lymphoma, the Children’s Oncology Group and the Innovative Therapies for Children and Adolescents with Cancer, alongside investigators from leading paediatric cancer centres across the United States, Canada, France, the Netherlands, Germany and beyond. The study is investigator-initiated and investigator-led, with core funding from Fight Kids Cancer and Cancer Research UK, and pharmaceutical partners supplying the investigational agents and supporting the fit-for-filing components of the first two arms.

Notably, the trial has embedded patient and public involvement from its inception. Representatives of patients and families, including contributors from parent-led foundations and the Coalition Against Childhood Cancer, have helped shape the study and its conduct, a reflection of a broader movement in paediatric oncology to ensure that research priorities align with what matters most to the young people affected. Trial governance includes a trial steering committee, a trial management group and an independent data monitoring committee, the standard safeguards that protect participant safety and study integrity as results accumulate across multiple arms and countries.

The significance of Glo-BNHL extends beyond any single drug. In this rare cancer setting, the platform presents a unique opportunity to evaluate multiple promising novel agents within the same trial, avoiding the years of delay and duplicated infrastructure that separate conventional one-drug, one-trial studies. Its designers state explicitly that the study is intended to generate sufficient evidence to be practice-changing, meaning that positive results could directly reshape how relapsed and refractory B-cell lymphoma is treated in young patients worldwide. For families confronting a relapse diagnosis, where time is the scarcest resource, the promise of a system that can rapidly identify which immunotherapies and targeted agents truly work represents a meaningful shift in how evidence for rare childhood cancers is built. As the first participants are enrolled and the Bayesian machinery begins to weigh each new data point, Glo-BNHL stands as a test case for whether global, adaptive, multi-stakeholder trial design can deliver answers faster for the children who need them most.

Subject of Research: Adaptive international platform trial testing novel targeted agents in paediatric relapsed and refractory B-cell non-Hodgkin lymphoma

Article Title: A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL): protocol for an adaptive international platform clinical trial

Article References: Burke, G. A. A., Seaford, E., Lax, S., Lawson, A., Williams, E., Rogers, J., Johnson, S., Deshpande, A., Ahmed, Z., Muzaffar, M., Maycock, S., Wang, J., Bollard, C. M., Allen, C. E., Auperin, A., Gore, L., Kearns, P., Beishuizen, A., Minard-Colin, V., … Billingham, L. (2026). A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL): protocol for an adaptive international platform clinical trial. BMC Cancer. https://doi.org/10.1186/s12885-026-16969-1

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16969-1

Keywords: B-cell non-Hodgkin lymphoma, platform trial, adaptive Bayesian design, bispecific antibodies, antibody-drug conjugates, CAR T-cells, paediatric oncology, relapsed refractory cancer, odronextamab, loncastuximab tesirine, ACCELERATE, clinical trial protocol

Nowhere is the de-escalation philosophy more visible than in the surgical management of the axilla, the lymph node basin under the arm whose removal has historically caused lymphoedema, numbness, and chronic morbidity. Building on the legacy of the ACOSOG Z0011 trial, the SENOMAC study delivered definitive high-level evidence that patients with small primary tumors and one or two sentinel-node macrometastases can safely skip full axillary lymph node dissection. In this large cohort, omitting the dissection offered no additional benefit in recurrence-free or overall survival, firmly establishing sentinel node biopsy alone as the standard for this common scenario. Yet the commentary adds an important caveat: nearly 90 percent of patients in the sentinel-biopsy-only arm received postoperative radiotherapy, meaning the safety of the approach is contingent on access to appropriate radiation. In resource-limited settings where comprehensive radiotherapy is restricted, the direct application of the SENOMAC protocol demands caution, a point with profound implications for global health equity.

Two further trials pushed the surgical frontier even further by asking whether sentinel node biopsy itself could be abandoned in select low-risk patients. The SOUND trial showed that in women with small, clinically node-negative tumors, omitting sentinel biopsy produced non-inferior five-year distant disease-free survival compared with performing the procedure, with rates of 98.0 percent versus 97.7 percent. The larger INSEMA trial confirmed the finding in a similar population undergoing breast-conserving surgery, demonstrating no difference in five-year invasive disease-free survival. For a well-defined group of early-stage patients, axillary surgery may now be safely omitted entirely. However, the commentary notes that INSEMA left key questions unresolved: enrollment of patients with slightly larger T2 tumors was low, the precise criteria for safely skipping axillary surgery remain unclear, and the resulting uncertainty in nodal staging can complicate subsequent treatment decisions. The path forward is promising but not yet fully mapped.

In hormone receptor-positive disease, the story of the past two years has been the consolidation of CDK4/6 inhibitors in the curative setting and the urgent search for what comes after they fail. Updated results from the monarchE trial, which tested two years of adjuvant abemaciclib, confirmed a sustained and significant reduction in recurrence risk, with the absolute benefit in invasive disease-free survival reaching 7.6 percent at five years, 83.6 percent versus 76.0 percent. The NATALEE trial, testing three years of adjuvant ribociclib, expanded eligibility to a broader intermediate-to-high-risk population and demonstrated a 4.9 percent absolute improvement in four-year invasive disease-free survival, alongside a 28.5 percent reduction in the risk of distant recurrence. Notably, a subgroup analysis of node-negative patients with high-risk features, a population excluded from monarchE, showed a substantial 5.1 percent absolute benefit, effectively covering a larger proportion of Stage II patients and addressing a critical unmet need.

With CDK4/6 inhibitors now ubiquitous in first-line metastatic treatment, defining the optimal strategy after progression has become a paramount research priority, and 2024 delivered several distinct answers. The postMONARCH trial was the first to prospectively validate simply continuing a CDK4/6 inhibitor: patients who progressed on prior CDK4/6 inhibition plus endocrine therapy gained a statistically significant but modest improvement in median progression-free survival when abemaciclib was added to fulvestrant, 6.0 versus 5.3 months. The benefit appeared concentrated in patients with longer prior CDK4/6 exposure and no visceral metastases, and the small absolute gain raises questions about universal utility, but the trial provides proof of concept that continued CDK pathway inhibition can help select patients. In parallel, the EMBER-3 trial showcased the oral selective estrogen receptor degrader imlunestrant, which significantly improved progression-free survival in tumors carrying ESR1 mutations, the classic driver of aromatase inhibitor resistance. More strikingly, combining imlunestrant with abemaciclib produced clear synergistic activity, extending median progression-free survival to 9.4 versus 5.5 months overall and 9.1 versus 3.7 months in the post-CDK4/6i subgroup, positioning oral SERDs as a powerful future backbone of therapy.

Perhaps the most practice-changing development was the expansion of the antibody-drug conjugate trastuzumab deruxtecan into tumors with barely detectable HER2 expression, including the newly defined HER2-ultralow category. The DESTINY-Breast06 trial enrolled patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic disease who had progressed on endocrine therapy and compared the drug with physician’s choice of chemotherapy. Trastuzumab deruxtecan delivered a median progression-free survival of 13.2 months versus 8.1 months, with results consistent across both expression groups and an objective response rate approaching 60 percent. The trial effectively redefines a large proportion of historically HER2-negative tumors as targetable, creating a highly effective, chemotherapy-sparing option for patients whose real-world outcomes on subsequent therapy have often been less than five months. Complementing this, the PAM signaling pathway, a key resistance mechanism, became druggable in routine practice: the AKT inhibitor capivasertib doubled progression-free survival when added to fulvestrant in CAPItello-291, with even greater benefit in tumors carrying AKT pathway alterations, while the PI3Kα inhibitor inavolisib, combined with palbociclib and fulvestrant in PIK3CA-mutated disease, delivered a remarkable median overall survival of 34.0 versus 27.0 months in the INAVO120 study. Given that PAM pathway alterations occur in roughly 60 percent of Chinese patient populations, these agents represent a major step toward genuinely personalized sequencing after CDK4/6 inhibitor failure.

In HER2-positive disease, the revolution runs in both directions: less treatment for early-stage patients, more potent treatment for the metastatic setting. The WSG-TP-II trial asked whether chemotherapy could be safely omitted for so-called triple-positive tumors sensitive to both endocrine therapy and HER2 blockade. Although the chemotherapy arm achieved a significantly higher pathological complete response rate, 56.0 percent versus 23.7 percent, five-year overall survival was remarkably similar and excellent in both groups, at 97.9 percent versus 100 percent. For selected patients, a chemotherapy-free neoadjuvant regimen of endocrine therapy plus dual HER2 blockade may therefore be a viable de-escalation strategy that spares significant toxicity without compromising survival. In the metastatic setting, the PHILA trial showed that the tyrosine kinase inhibitor pyrotinib, added to trastuzumab and docetaxel, doubled median progression-free survival to 22.1 versus 10.5 months, while DESTINY-Breast09 demonstrated that first-line trastuzumab deruxtecan plus pertuzumab extended median progression-free survival to an unprecedented 40.7 versus 26.9 months, providing direct evidence for moving the antibody-drug conjugate from second line to first line. Updated DESTINY-Breast03 data cemented the drug’s second-line dominance, with median progression-free survival of 29.0 versus 7.2 months against trastuzumab emtansine and median overall survival of 52.6 months, a figure approaching first-line results from the CLEOPATRA era.

Triple-negative breast cancer, long the most feared subtype for its aggressive biology and lack of targets, finally saw both immunotherapy and precision medicine mature. Final overall survival results from KEYNOTE-522 confirmed that adding pembrolizumab to neoadjuvant chemotherapy, followed by adjuvant pembrolizumab, produced a significant five-year overall survival benefit of 86.6 percent versus 81.7 percent, regardless of PD-L1 status, cementing the regimen as the global standard of care. In China, the CamRelief trial showed that the PD-1 inhibitor camrelizumab significantly increased pathological complete response rates when added to neoadjuvant chemotherapy, 56.8 percent versus 44.7 percent, while the antibody-drug conjugate Dato-DXd showed promise in the neoadjuvant I-SPY2.2 platform. In the metastatic setting, TORCHLIGHT established toripalimab plus nab-paclitaxel as a new standard for PD-L1-positive patients in China, with progression-free survival of 8.4 versus 5.6 months.

The most revolutionary TNBC result, however, came from the FUTURE-SUPER trial, which applied the molecular Fudan Subtypes model to guide first-line therapy for metastatic disease. Patients were stratified into biologically defined groups, including luminal androgen receptor tumors with HER2 or PI3K/AKT mutations, immunomodulatory tumors, and basal-like or mesenchymal-like subgroups, and each received subtype-specific treatment rather than uniform chemotherapy. The precision arm nearly doubled median progression-free survival, 11.3 versus 5.8 months, breaking a long-standing impasse in targeted therapy for this subtype. Later-line options also expanded dramatically: the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan improved progression-free survival to 5.7 versus 2.3 months over chemotherapy in OptiTROP-Breast01, and ASCENT-04/KEYNOTE-D19 showed that sacituzumab govitecan combined with pembrolizumab extended first-line progression-free survival to 11.2 versus 7.8 months in previously untreated, PD-L1-positive advanced disease, offering a novel chemotherapy-sparing option.

The commentary’s authors close with a sober assessment of what remains. The challenge ahead lies in optimally sequencing these powerful new agents, identifying predictive biomarkers to guide their use, and ensuring that transformative therapies reach all patients who stand to benefit. Global disparities in regulatory approval and the burden of financial toxicity remain critical hurdles, and the cautionary notes embedded in the surgical trials, particularly the dependence of de-escalation on radiotherapy access, underscore that scientific evidence alone cannot guarantee equitable care. Still, the trajectory is unmistakable: breast cancer treatment in 2025 is increasingly personalized, potent, and patient-centered, defined as much by what clinicians can now safely withhold as by what they can newly offer.

Subject of Research: Precision-guided de-escalation and targeted therapy advances in breast cancer treatment

Article Title: Breast cancer in 2025: navigating new horizons of precision-guided de-escalation

Article References: Wang, Z., Yang, B., & Wu, J. (2026). Breast cancer in 2025: navigating new horizons of precision-guided de-escalation. Holistic Integrative Oncology, 5(1), Article 41. https://doi.org/10.1007/s44178-026-00258-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00258-9

Keywords: breast cancer, de-escalation, CDK4/6 inhibitors, antibody-drug conjugates, trastuzumab deruxtecan, triple-negative breast cancer, immunotherapy, HER2-low, axillary surgery, precision medicine, SERDs, PI3K/AKT pathway

HER2, a growth factor receptor encoded by the ERBB2 gene, is amplified or overexpressed in roughly 15 to 20 percent of breast cancers. That molecular signature once heralded an aggressive disease course, but the arrival of trastuzumab, pertuzumab, and a growing arsenal of HER2-targeted agents transformed the prognosis. Today, giving these drugs before surgery—neoadjuvant therapy—is standard practice for stage I to III HER2-positive disease, because it can shrink tumors, sometimes eliminating them entirely, and allows oncologists to gauge response in real time. Yet a meaningful fraction of patients still reach the operating table with residual invasive carcinoma in the breast or lymph nodes.

For those patients, the landmark KATHERINE trial established trastuzumab emtansine (T-DM1) as the standard of care, improving invasive disease-free survival and overall survival compared with trastuzumab alone. More recently, the DESTINY-Breast05 trial showed that trastuzumab deruxtecan (T-DXd) outperformed T-DM1 in patients with residual HER2-positive early disease. Critically, however, both frameworks assumed that a tumor classified as HER2-positive before treatment remained HER2-positive afterward. The MD Anderson study directly tested that assumption—and found it wanting.

The research team, led by pathologist Payu Raval and senior author Aysegul Sahin, retrospectively examined 161 patients treated with HER2-targeted neoadjuvant therapy between 2016 and 2025. Sixty-five of them had enough residual invasive tumor for reliable biomarker reassessment. Using the same clinically validated immunohistochemistry protocol applied in routine care, two study pathologists independently scored HER2 expression in the surgical specimens under the 2018 ASCO/CAP guidelines, with a third pathologist resolving any discordant readings. Every equivocal case—those scored IHC 2+—underwent reflex fluorescence in situ hybridization to determine whether the ERBB2 gene remained amplified.

The results were striking. Thirty-seven of the 65 tumors, or 57 percent, showed a change in HER2 status, shifting from overexpression or amplification before treatment to IHC 0, IHC 1+, or IHC 2+ without gene amplification afterward. Only 28 cases, 43 percent, retained clear HER2 positivity. The pattern depended on where tumors started: among the 33 tumors that were strongly HER2 IHC 3+ at baseline, just under half lost HER2, whereas among the 32 tumors classified as IHC 2+/FISH-amplified, more than two-thirds—68.8 percent—did so. Several of the converted tumors even fell into the emerging HER2-ultralow category, expressing barely detectable levels of the protein.

Perhaps the most sobering aspect of the study is what the researchers could not find. When the team compared the HER2-retained and HER2-changed groups across a battery of clinicopathologic variables—age, clinical stage, histologic subtype, Nottingham grade, hormone receptor status, residual cancer burden, and type of surgery—the two groups were essentially indistinguishable. Hormone receptor positivity was common in both, present in 82.1 percent of the retained group and 89.2 percent of the changed group, and the distribution of residual cancer burden categories was nearly identical. In other words, there is no easy clinical flag that tells oncologists in advance which tumors will shed their target.

Why does this happen? The leading explanation is intratumoral heterogeneity: a single tumor can harbor mixed populations of cells with differing levels of HER2 expression and ERBB2 amplification. Potent HER2 blockade wipes out the dependent cells, while subclones with little or no HER2 survive and repopulate the residual disease—a classic case of clonal selection under therapeutic pressure. Supporting this model, a phase II trial of T-DM1 plus pertuzumab found zero pathologic complete responses in tumors with HER2 heterogeneity, compared with 55 percent in homogeneous tumors. Other work has shown that HER2 heterogeneity is far more prevalent in tumors with low-level amplification, which may explain why the IHC 2+/FISH-amplified group in the new study was so vulnerable to status change. Resistant subclones, genomic studies suggest, often exist before treatment even begins.

The clinical stakes are considerable. Current national and international guidelines recommend adjuvant HER2-targeted therapy for residual disease regardless of post-treatment HER2 status, largely because trials like KATHERINE enrolled patients based on their original diagnosis and never required repeat testing. Whether T-DM1 or T-DXd actually benefits tumors that have lost HER2 remains unknown. There are reasons for cautious optimism: antibody-drug conjugates deliver cytotoxic payloads via the HER2 antibody, so even low levels of the protein may suffice for activity, and the DESTINY-Breast04 trial demonstrated survival benefits of T-DXd in HER2-low metastatic disease. Real-world data from China reported remarkably low recurrence rates among patients who continued HER2-directed therapy despite conversion. But preclinical studies complicate the picture, indicating that HER2-low cells may resist ADCs while remaining susceptible to HER2 kinase inhibitors—hinting that combination strategies may ultimately be needed.

Prognostic evidence is equally unsettled. Several meta-analyses have linked HER2 loss after neoadjuvant therapy to worse recurrence-free and overall survival, with hazard ratios approaching 2, and one registry analysis of more than 21,000 Japanese patients found that 21.4 percent of initially HER2-positive tumors became HER2-negative after treatment. Yet other cohorts, including a surgical series from 2021, found no oncologic penalty for losing HER2 positivity, and some even reported better outcomes with reduced expression. These contradictions likely reflect differences in definitions, therapy intensity, and sampling, but they underscore that complete loss and partial reduction of HER2 may carry different prognostic meanings. Intriguingly, one study found that shorter intervals between therapy and tissue sampling were associated with greater HER2 loss, raising the possibility that some of the change is a reversible pharmacodynamic effect rather than permanent clonal elimination.

The MD Anderson authors are careful about their limitations: the study was retrospective, single-institution, and modest in size, excluded residual tumors smaller than 5 millimeters, and lacked outcome data and molecular profiling. Still, their conclusion is pointed. HER2 should be viewed not as a fixed binary label but as a dynamic continuum reshaped by treatment, and routine reassessment of residual disease deserves serious consideration. Prospective randomized phase II and III trials, they argue, are now needed to determine whether patients whose tumors lose HER2 actually benefit from continuing HER2-targeted therapy—or whether, in the era of antibody-drug conjugates, the biopsy taken after neoadjuvant treatment should become the new starting point for every adjuvant decision.

Subject of Research: HER2 biomarker status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy

Article Title: HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer

Article References: Raval, P., Ding, Q., Singh, P., Alrohaibani, A., Sun, H., Ai, D., Wanis, K. N., Zhao, M., Chen, H., Valero, V., Chavez-MacGregor, M., & Sahin, A. (2026). HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer. Breast Cancer Research and Treatment, 219(3), Article 25. https://doi.org/10.1007/s10549-026-08088-z

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08088-z

Keywords: HER2-positive breast cancer, neoadjuvant therapy, HER2 status change, biomarker discordance, immunohistochemistry, FISH, trastuzumab, pertuzumab, antibody-drug conjugates, intratumoral heterogeneity, residual disease, adjuvant therapy

The biological logic behind MSI-H/dMMR immunotherapy is the strongest in the field. When the mismatch repair machinery fails, cells accumulate insertion and deletion mutations that generate frameshift neoantigens, provoking a characteristic immune state: dense CD8-positive T-cell infiltration, heightened interferon signalling and adaptive upregulation of PD-1. Crucially, this immune phenotype is conserved across many tumour types, which is why pembrolizumab produced durable responses in roughly one-third of patients across more than 25 malignancies in the KEYNOTE-158 trial, with a median duration of response of 63.2 months. The paradigm extended beyond a single drug when the FDA granted accelerated approval to dostarlimab for previously treated recurrent or advanced dMMR solid tumours in 2021, supported by the GARNET study, in which the objective response rate reached 44 percent with responses lasting a median of 27.7 months. This, the authors argue, is what a genuine tumour-agnostic biomarker looks like: a shared, immune-sensitive biological state rather than a shared mutation.

Tumour mutational burden tells the opposite story. The premise was seductive: more mutations should yield more neoantigens and greater sensitivity to checkpoint blockade. But the pan-cancer experience exposed a fundamental flaw in that reasoning. A threshold of 10 mutations per megabase conflates biologically disparate cancers with different mutational processes, neoantigen quality, antigen-presentation machinery and immune microenvironments. TMB quantifies mutation burden while ignoring immunogenicity, T-cell infiltration and immune exclusion, all of which determine clinical response. In KEYNOTE-158, 102 patients with TMB-high tumours across ten histologies achieved an objective response rate of 29 percent, which was enough for the FDA’s 2020 accelerated approval of pembrolizumab for TMB-high solid tumours without satisfactory alternatives. Real-world datasets, however, show substantial heterogeneity by tumour type, with predictive value remaining strong mainly in cancers already characterised by immune infiltration. The immune ecosystem of a pancreatic adenocarcinoma differs fundamentally from that of a melanoma, regardless of whether a shared biomarker is present.

The review proposes that immunotherapy biomarkers be understood as layered rather than binary, spanning four domains. Tumour-intrinsic markers include MSI-H/dMMR, TMB, POLE and POLD1 mutations, viral antigens, DNA damage repair defects, mutational signatures and HLA loss. Immune microenvironment markers include PD-L1 expression, tumour-infiltrating lymphocytes, CD8 T-cell localisation, interferon signalling, myeloid infiltration and tertiary lymphoid structures. Host and systemic markers encompass immune fitness, microbiome composition, corticosteroid exposure and autoimmune risk, while dynamic markers include circulating tumour DNA kinetics, early radiographic patterns and immune-related toxicity. This layered model explains why single biomarkers perform inconsistently in tumour-agnostic practice. A high TMB result, for example, may be far less informative when it reflects treatment-induced hypermutation, such as temozolomide-associated hypermutation in recurrent glioma, rather than a clonal, endogenous immune-sensitive state.

The validation gap between candidate biomarkers is stark. PD-L1 protein expression has established tumour-specific assays and clinical utility, but its predictive value depends on the assay clone, scoring method, threshold and tumour lineage, and no PD-L1-expression-defined pan-cancer indication exists. PD-L1 gene amplification is rarer still, found in roughly 0.7 percent of tumours across more than 100 histologies in one pan-cancer series, and retrospective data suggest greater checkpoint inhibitor activity in amplified tumours, but no validated selection standard has emerged. Pathogenic POLE and POLD1 proofreading defects produce ultramutated, immunogenic phenotypes and correlate with checkpoint inhibitor efficacy, yet no regulatory indication rests on them alone, and the evidence is strongest in colorectal and endometrial cancers. Viral association, T-cell-inflamed gene signatures and tertiary lymphoid structures all carry biological plausibility and supportive evidence, but none constitutes a validated tumour-agnostic biomarker suitable for standalone prescribing.

Rare cancers expose the paradigm’s sharpest dilemma. Many are systematically excluded from pivotal trials yet demonstrate immunotherapy sensitivity without validated predictive biomarkers, as seen in Merkel cell carcinoma, alveolar soft-part sarcoma, thymic carcinoma and selected neuroendocrine subtypes. The SWOG S1609 DART trial, a phase 2 basket study of ipilimumab plus nivolumab across 53 rare cancer cohorts, enrolled 798 patients and confirmed responses in 24 of 53 cohorts, with an overall response rate of 13 percent and durable benefit in angiosarcoma, neuroendocrine tumours and rare gynaecological malignancies. The Australian MoST-CIRCUIT trial reported an objective response rate of 54 percent in advanced ovarian and endometrial clear cell cancers, most of which were mismatch repair-proficient and low TMB, and 63 percent in non-colorectal dMMR/MSI-H cancers across 17 tumour types. These results reveal immune-sensitive cohorts while leaving clinicians without biomarkers capable of identifying individual responders.

This is what the authors call the clinical grey zone: a patient with a rare cancer, exhausted standard options, emerging evidence of immunotherapy activity, no validated biomarker, no reimbursed molecular test and no feasible trial. A strictly biomarker-defined access model may be too restrictive, but unrestricted prescribing risks unwarranted toxicity, false hope and low-value care. The authors propose a pragmatic framework weighing four linked domains: strength of clinical evidence, biological and biomarker evidence within tumour-lineage context, competing treatment options, and patient-specific benefit-risk. Treatment can be recommended when convincing evidence or a validated immune-sensitive state exists and no superior option is available; considered with multidisciplinary review when uncertainty remains; and avoided outside a trial when evidence is absent, a superior therapy exists, or toxicity risk outweighs plausible benefit. The framework is deliberately not a numerical score, because strong evidence in one domain may override uncertainty in another.

Australia has become the world’s most consequential test case. In 2026, the Pharmaceutical Benefits Scheme consolidated and expanded public reimbursement of ipilimumab plus nivolumab and pembrolizumab for eligible patients with advanced or metastatic cancers considered immunotherapy-sensitive, including rare and uncommon cancers lacking conventional trial data. The listing, described as a world first and the product of partnership between government, industry, clinicians and patient advocates, includes shared costs between government and sponsor and a reassessment after three years. Critically, the reimbursement change did not create a corresponding tumour-agnostic regulatory indication, and the listing does not require a positive biomarker. Because broad pan-cancer next-generation sequencing is not universally funded in Australia, the country may be the first to fund pan-cancer immunotherapy without simultaneously funding the biomarker testing infrastructure needed to deploy it, transferring substantial selection responsibility to treating clinicians.

The economics of immunotherapy are also shifting. Annual treatment costs for PD-1 and PD-L1 inhibitors in the United States commonly exceed US$100,000 per patient, and multiple cost-effectiveness analyses have questioned the sustainability of broad population-level use at originator prices. Competition, biosimilar development and alternative procurement models may progressively reduce price as the sole determinant of access. As financial barriers ease, the question of appropriate use intensifies: severe immune-related adverse events occur in 15 to 20 percent of patients receiving checkpoint inhibitors, with fatal outcomes in 0.3 to 1.2 percent of cases. Reimbursement policy, the authors argue, cannot be considered independently of patient selection, and structured decision frameworks become the mechanism for translating genomic and immunologic data into responsible clinical guidance.

The lessons extend beyond checkpoint inhibitors to emerging pan-tumour platforms, including antibody-drug conjugates, bispecific antibodies and cellular therapies. Shared target expression among tumour types does not necessarily define a conserved therapeutic vulnerability: for antibody-drug conjugates, target density, internalisation kinetics, spatial heterogeneity, payload sensitivity and tumour lineage all influence efficacy despite expression of the same antigen. The review’s conclusion is measured but pointed. Tumour-agnostic immunotherapy has not made tumour type obsolete; it has shown that in selected settings biology can be more clinically informative than anatomy. Whether Australia’s experiment succeeds will depend on four prerequisites: funded molecular testing, expert decision support, prospective registries capturing outcomes and toxicity, and mechanisms for reassessment. Without those safeguards, the authors warn, the model risks both waste and harm, funding the drug before funding the pathway that decides who should receive it.

Subject of Research: Tumour-agnostic immunotherapy biomarkers and implementation of pan-cancer checkpoint inhibitor reimbursement

Article Title: Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation

Article References: Liu, J., Beal, J., Coleman, N., Lynam, J., & Subbiah, V. (2026). Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation. eClinicalMedicine, 100, Article 104211. https://doi.org/10.1016/j.eclinm.2026.104211

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104211

Keywords: tumour-agnostic immunotherapy, MSI-H/dMMR, tumour mutational burden, checkpoint inhibitors, pembrolizumab, biomarkers, rare cancers, basket trials, Australia PBS reimbursement, precision oncology, tumour microenvironment, antibody-drug conjugates

Antibody-drug conjugates, or ADCs, are often described as guided missiles: a monoclonal antibody engineered to recognize a specific surface protein is chemically linked to a potent cytotoxic payload, allowing the drug to deliver its lethal cargo preferentially to cells bearing the target. Three such targets have already demonstrated clinical efficacy in urothelial carcinoma—NECTIN4, TACSTD2 (better known as TROP-2), and ERBB2 (HER2). Yet the authors of the new study noted a conspicuous gap: few investigations had systematically mapped how these targets behave at single-cell resolution in relation to tumor differentiation states, intrinsic biological programs, and the surrounding immune microenvironment. That gap matters, because a target that glows brightly in one region of a tumor may be nearly invisible in another, even within the same patient.

To build their atlas, the team integrated single-cell RNA sequencing data from three public cohorts, applying Harmony batch correction to merge datasets generated in different laboratories without erasing genuine biological differences. Quality-control metrics, benchmarking against an alternative integration method, and copy-number-variation-based validation of malignancy all supported the robustness of the merged dataset. Within the epithelial compartment, the researchers assigned consensus molecular subtype classifications at single-cell resolution, distinguishing basal, luminal, and neuroendocrine-like tumor populations. They then applied pseudotime trajectory inference using the Slingshot algorithm to order tumor cells along a basal-to-luminal differentiation axis, effectively reconstructing a maturation timeline from the static snapshot of sequencing data.

What emerged from that trajectory analysis was a striking divergence in how the three ADC targets are distributed along the differentiation axis. TROP-2, encoded by TACSTD2, was expressed broadly across the entire trajectory, making it the most uniform of the targets—a property reflected in its low inter-patient heterogeneity, with a Gini index of just 0.27 compared with 0.67 for NECTIN4, the most variable target. ERBB2/HER2, by contrast, was sharply localized to a narrow window along the trajectory, and that window coincided with elevated activity of ABC transporter genes—a family of drug efflux pumps with obvious relevance to chemotherapy resistance. NECTIN4 told a third story: it was virtually absent in early basal cells and rose progressively through the partial-epithelial-to-mesenchymal-transition zone, the transitional state that many tumor biologists associate with plasticity and metastatic potential.

These expression patterns were not merely descriptive. Patient-level analyses linked TROP-2 expression to elevated epithelial-mesenchymal transition program activity and HER2 expression to elevated ABC transporter activity, with modest associations to interferon-gamma signaling. The team validated their findings across species, showing that broad TROP-2 expression enriched in more differentiated cells is conserved in normal human and mouse urothelium, suggesting it reflects a fundamental physiological property of urothelial differentiation rather than a tumor-specific quirk. Bootstrap analyses resampling the 21 patients 200 times confirmed that the breadth-versus-focality differences between targets were statistically supported, though the peak positions of NECTIN4 and HER2 along pseudotime could not be cleanly separated from one another.

Perhaps the most provocative result came from the CellChat analysis of tumor-immune communication. The researchers, including a custom-curated ligand-receptor pair, found that NECTIN4-TIGIT ranked as the top predicted tumor-to-immune inhibitory checkpoint interaction, with tumor epithelial cells serving as the exclusive predicted source of NECTIN4-mediated TIGIT engagement. TIGIT is an inhibitory receptor on T cells and natural killer cells, and the finding implies that the very molecule drug developers exploit to shuttle toxins into tumors may simultaneously be helping the cancer suppress the immune cells that ADCs rely on for antibody-dependent cellular cytotoxicity. If confirmed experimentally, this dual role would provide a mechanistic rationale for combining NECTIN4-directed ADCs with TIGIT blockade.

The communication analysis also surfaced an unexpected player: the APP-CD74 axis, in which amyloid precursor protein—a molecule famous for its role in Alzheimer’s disease—emerged as a tumor-derived signal engaging CD74 on immune cells. The researchers detected 26 significant intercellular interactions along this axis, and validation in the TCGA-BLCA bulk transcriptomic cohort of 403 to 412 patients showed that tumors with high APP and low CD74 expression had the worst overall survival, with a hazard ratio of 2.00 (95 percent confidence interval 1.31 to 3.04, p equals 0.001). The authors were careful in their framing: the data suggest that disruption of this axis is associated with worse survival, not that it is causally responsible, but the association was strong enough to flag APP-CD74 as a novel prognostic communication axis worthy of functional follow-up.

The differentiation theme extended to patient outcomes in the TCGA-BLCA validation cohort. When the researchers distilled their pseudotime analysis into a differentiation signature and applied it to bulk tumor data, they found that early-differentiation tumors—those dominated by basal-like cells—carried significantly worse overall survival, with a hazard ratio of 1.58 (95 percent confidence interval 1.12 to 2.24, p equals 0.009), a result that held in multivariate models adjusting for molecular subtype, pathologic stage, and age. These early-differentiation tumors were enriched for epithelial-mesenchymal transition activity (Spearman rho of negative 0.398 with the differentiation index), interferon-gamma response (rho of negative 0.430), and proliferation signatures (rho of negative 0.502). Intriguingly, they also harbored elevated tumor mutational burden, hinting that despite their aggressive biology, these tumors might still respond to immune checkpoint inhibitors—a nuance that could matter for sequencing therapy in the clinic.

For the ADC field, the takeaway is that target expression breadth should inform biomarker-guided stratification. A target like TROP-2, expressed broadly across the differentiation spectrum and consistently across patients, offers a wide therapeutic window in principle; a target like HER2, confined to a narrow differentiation window and coupled to drug-efflux machinery, may require more careful patient selection and combination strategies to overcome resistance. NECTIN4’s dependence on differentiation state helps explain why it is the most heterogeneous target between patients, and why a biopsy from one region of a tumor might substantially overestimate or underestimate the true burden of target-positive cells. The pseudotime-derived differentiation signature, the authors propose, could serve as a biomarker to guide ADC therapy selection in urothelial carcinoma, complementing the molecular subtyping frameworks already in clinical discussion.

The study is not without caveats, several of which the authors acknowledge in their supplementary analyses. The atlas, while among the largest for this disease, derives from 21 patients, and pseudotime inference reconstructs a trajectory that cells may not literally traverse in vivo. The NECTIN4-TIGIT and APP-CD74 findings are computational predictions that will need wet-lab confirmation, and the published version remains subject to final editorial revision. Still, the work exemplifies a broader shift in oncology: from viewing tumors as uniform masses bearing static molecular flags, to reading them as ecosystems in which drug targets, immune evasion programs, and differentiation states are woven together—and in which the most effective therapies will be those designed with that dynamism in mind.

Subject of Research: Single-cell transcriptomic mapping of antibody-drug conjugate target dynamics and tumor-immune checkpoint interactions in muscle-invasive bladder cancer

Article Title: Single-cell transcriptomic profiling of muscle-invasive bladder cancer reveals differentiation-dependent ADC target dynamics and tumor-immune checkpoint interactions

Article References: Chang, P. M.-H., Yen, C.-C., Wu, W.-C., & Lai, J.-I. (2026). Single-cell transcriptomic profiling of muscle-invasive bladder cancer reveals differentiation-dependent ADC target dynamics and tumor-immune checkpoint interactions. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08916-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08916-2

Keywords: bladder cancer, single-cell RNA sequencing, antibody-drug conjugates, NECTIN4, TROP-2, HER2, TIGIT, APP-CD74 axis, pseudotime trajectory, tumor microenvironment, biomarkers, urothelial carcinoma